CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each):
  • 8 weeks ≈ 3 vials
  • 12 weeks ≈ 4 vials
  • 16 weeks ≈ 5 vials
• Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

CJC-1295 NO DAC + Ipamorelin 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

PeptideDosages has no affiliation with Pure Lab Peptides and receives no commission from these Pure Lab links. Supplier pages are not scientific evidence or proof of suitability for human use.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).
• Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
• Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)^[1][2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases^[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol^[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Concise summary of the once-daily regimen.

• Goal: Support pulsatile GH release through synergistic GHRH + GHS stimulation^[4].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 100–300 mcg of each peptide daily with gradual titration.
• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested daily titration approach.

• Start: 100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated.
• Target: 200–300 mcg each peptide daily by Weeks 5–12.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Typically before bed or upon waking; rotate injection sites.

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• For doses under 10 units, use 30- or 50-unit syringes for better precision.

CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary^[1]. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration^[1]. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours^[5] that elicits a rapid GH pulse peaking around 40 minutes post-dose^[6]. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels^[3]. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways^[4].

Observations from preclinical and clinical literature.

• Supports sustained GH and IGF-1 elevation through pulsatile release patterns^[1][2].
• Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation^[3].
• Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models^[2].
• Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.
• Some individuals report increased appetite, water retention, or tingling sensations.

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy needs.
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep quality, as GH is predominantly released during deep sleep.
• Manage stress to support optimal hormonal balance and recovery.

General subcutaneous guidance from clinical best-practice resources^[7].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[7][8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[7].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[9].

We recommend Pure Lab Peptides for high-purity CJC-1295 NO DAC + Ipamorelin (10 mg Blend).

Shop at Pure Lab Peptides

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

• 1
  
  PubMed
  — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults

  View Source
• 2
  
  PubMed
  — Once-daily CJC-1295 normalizes growth in GHRH knockout mouse

  View Source
• 3
  
  PubMed
  — Ipamorelin, the first selective growth hormone secretagogue

  View Source
• 4
  
  PMC
  — Beyond the androgen receptor: GH secretagogues in body composition management

  View Source
• 5
  
  PubMed
  — Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers

  View Source
• 6
  
  PubMed
  — Ipamorelin GH pulse kinetics and timing studies

  View Source
• 7
  
  CDC
  — Vaccine administration: subcutaneous route (angle/site; no aspiration)

  View Source
• 8
  
  CDC (Subcut Injection PDF)
  — Technique diagram and site guidance for subcutaneous injections

  View Source
• 9
  
  NCBI Bookshelf
  — Best practices for injection (asepsis, preparation, and administration)

  View Source
• 13
  
  Pure Lab Peptides
  — CJC-1295 NO DAC + Ipamorelin (10 mg Blend) product page

  View Source

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above.

• 1
  
  Subcutaneous Drug Injection Review (PMC)
  — Pharmacologic considerations of the subcutaneous route

  View Source
• 2
  
  Frontiers in Endocrinology
  — Growth hormone secretagogues: history and clinical applications

  View Source
• 3
  
  Endocrine Reviews
  — Ghrelin and growth hormone secretagogues: physiology and applications

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.